{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:03:12Z","timestamp":1790071392228,"version":"4.0.1"},"reference-count":109,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The expanding molecular classification of renal neoplasia has created a growing need for biomarkers that translate biologic insights into practical diagnostic tools. This review focuses on recently introduced immunohistochemical (IHC) and RNA in situ hybridization (RNA-ISH) assays with potential relevance to routine kidney tumor pathology. Biomarkers were selected based on their applicability to conventional formalin-fixed, paraffin-embedded tissue; commercial accessibility and potential for cost-effective implementation; evaluation in substantial tumor cohorts; comparison with established or gold-standard methods; and, where available, validation in independent and\/or multi-institutional studies. The reviewed biomarkers encompass markers of cellular lineage and differentiation (L1CAM, FOXI1, and LINC01187); markers of tumor identity, molecular alterations, and metabolic pathway dysregulation (GPNMB, AKR1B10, 2SC, VSTM2A, TRIM63, and Merlin); and prognostic or therapeutically relevant biomarkers (BAP1, HER2, ABCC2, and PD-L1). We critically evaluate their biologic rationale, diagnostic, prognostic, and predictive applications, technical limitations, and current level of validation. By distinguishing biomarkers supported for broader or selective clinical implementation from those requiring additional validation or remaining primarily relevant to defined therapeutic contexts, this review provides a practical framework for their integration into contemporary renal tumor pathology.<\/jats:p>","DOI":"10.3390\/cancers18193072","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:04:17Z","timestamp":1790067857000},"page":"3072","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Immunohistochemical and RNA in Situ Hybridization Assays for Renal Neoplasia: Which Biomarkers Are Ready for Prime Time?"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3712-7973","authenticated-orcid":false,"given":"Jacob E.","family":"Valk","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0819-9638","authenticated-orcid":false,"given":"Maria S.","family":"Tretiakova","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"ref_1","first-page":"237","article-title":"The Human Chromophobe Cell Renal Carcinoma: Its Probable Relation to Intercalated Cells of the Collecting Duct","volume":"56","author":"Steart","year":"1989","journal-title":"Virchows Arch. B Cell Pathol. Incl. Mol. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-199701000-00001","article-title":"Renal Oncocytoma: A Reappraisal of Morphologic Features with Clinicopathologic Findings in 80 Cases","volume":"21","author":"Amin","year":"1997","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_4","unstructured":"Organisation Mondiale de la Sant\u00e9, and Centre International de Recherche sur le Cancer (2022). Urinary and Male Genital Tumours, World Health Organization Classification of Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cll.2005.01.006","article-title":"Oncocytic Renal Neoplasms: Diagnostic Considerations","volume":"25","author":"Abrahams","year":"2005","journal-title":"Clin. Lab. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/his.13727","article-title":"New and Emerging Renal Entities: A Perspective Post-WHO 2016 Classification","volume":"74","author":"Trpkov","year":"2019","journal-title":"Histopathology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1460-2075.1984.tb01753.x","article-title":"Immunocytological and Biochemical Characterization of a New Neuronal Cell Surface Component (L1 Antigen) Which Is Involved in Cell Adhesion","volume":"3","author":"Rathjen","year":"1984","journal-title":"EMBO J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2008.12.021","article-title":"L1 Cell Adhesion Molecule (L1CAM) in Invasive Tumors","volume":"282","author":"Raveh","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/ijc.29658","article-title":"L1CAM in Human Cancer","volume":"138","author":"Altevogt","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1083\/jcb.143.7.2067","article-title":"The Cell Adhesion Molecule L1 Is Developmentally Regulated in the Renal Epithelium and Is Involved in Kidney Branching Morphogenesis","volume":"143","author":"Debiec","year":"1998","journal-title":"J. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.1190.11.3","article-title":"The L1 Cell Adhesion Molecule Is Induced in Renal Cancer Cells and Correlates with Metastasis in Clear Cell Carcinomas","volume":"11","author":"Allory","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100467","DOI":"10.1016\/j.modpat.2024.100467","article-title":"L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma","volume":"37","author":"Alghamdi","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Scuccimarri, L., d\u2019Amati, A., Pierconti, F., Santoro, A., Ciampi, L., Montrone, T., Zito, F.A., Lucarelli, G., Rindi, G., and Zannoni, G.F. (2025). L1CAM Reliably Distinguishes Low-Grade Oncocytic Tumor from Other Eosinophilic Renal Neoplasms: A Multicenter Immunohistochemical Study with Diagnostic Implications. Cancers, 17.","DOI":"10.3390\/cancers17152440"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104596","DOI":"10.1016\/j.ebiom.2023.104596","article-title":"Comparative Analyses Define Differences between BHD-Associated Renal Tumour and Sporadic Chromophobe Renal Cell Carcinoma","volume":"92","author":"Jikuya","year":"2023","journal-title":"EBioMedicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/PAS.0000000000002152","article-title":"Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dub\u00e9 Syndrome Patients-A Tale of Two Cities: Sequencing Analysis Reveals Dual Lineage Markers Capturing the 2 Cellular Populations of HOT","volume":"48","author":"Wang","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2025.03.012","article-title":"Renal Neoplasia in Birt-Hogg-Dub\u00e9 Syndrome: Integrated Histopathologic, Bulk, and Single-Cell Transcriptomic Analysis","volume":"88","author":"Gupta","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00428-026-04588-x","article-title":"Clinicopathologic Characterization of Renal Tumors with Folliculin (FLCN) Biallelic Inactivation","volume":"489","author":"Siegmund","year":"2026","journal-title":"Virchows Arch."},{"key":"ref_18","first-page":"S1065","article-title":"Renal Oncocytosis and Birt-Hogg-Dub\u00e9 Syndrome: Characterization and Comparison in a Contemporary Cohort","volume":"104","author":"Valk","year":"2024","journal-title":"Lab. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/PAS.0000000000001288","article-title":"Papillary Renal Neoplasm With Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study","volume":"43","author":"Eble","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100540","DOI":"10.1016\/j.modpat.2024.100540","article-title":"Expression of L1 Cell Adhesion Molecule, a Nephronal Principal Cell Marker, in Nephrogenic Adenoma","volume":"37","author":"Mannan","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00428-025-04078-6","article-title":"Succinate Dehydrogenase Deficient Renal Cell Carcinoma Frequently Expresses GATA3 and L1CAM","volume":"486","author":"Sangoi","year":"2025","journal-title":"Virchows Arch."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105194","DOI":"10.1016\/j.labinv.2025.105194","article-title":"906 L1CAM Expression by Immunohistochemistry Exhibits Complex Patterns and Different Diagnostic Utilities in Renal Epithelial Neoplasms","volume":"106","author":"Yang","year":"2026","journal-title":"Lab. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105177","DOI":"10.1016\/j.labinv.2025.105177","article-title":"889 L1CAM Immunohistochemistry Performance in a Large Renal Tumor Validation Cohort","volume":"106","author":"Valk","year":"2026","journal-title":"Lab. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1172\/JCI20665","article-title":"Distal Renal Tubular Acidosis in Mice That Lack the Forkhead Transcription Factor Foxi1","volume":"113","author":"Blomqvist","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.febslet.2013.05.007","article-title":"Cell Biology of the Intercalated Cell in the Kidney","volume":"587","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00428-020-02900-x","article-title":"FOXI1 Expression in Chromophobe Renal Cell Carcinoma and Renal Oncocytoma: A Study of The Cancer Genome Atlas Transcriptome-Based Outlier Mining and Immunohistochemistry","volume":"478","author":"Tong","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2020.03.003","article-title":"Next-Generation RNA Sequencing-Based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms","volume":"78","author":"Skala","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/10668969221125793","article-title":"Characterization of Intercalated Cell Markers KIT and LINC01187 in Chromophobe Renal Cell Carcinoma and Other Renal Neoplasms","volume":"31","author":"Mannan","year":"2023","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.2910600111","article-title":"Nmb, a Novel Gene, Is Expressed in Low-Metastatic Human Melanoma Cell Lines and Xenografts","volume":"60","author":"Weterman","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i4.50","article-title":"Functional Roles of Osteoactivin in Normal and Disease Processes","volume":"20","author":"Singh","year":"2010","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_31","first-page":"839","article-title":"Glycoprotein Non-Metastatic b (GPNMB): A Metastatic Mediator and Emerging Therapeutic Target in Cancer","volume":"6","author":"Maric","year":"2013","journal-title":"Onco Targets Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1038\/s41388-022-02443-2","article-title":"GPNMB: A Potent Inducer of Immunosuppression in Cancer","volume":"41","author":"Lazaratos","year":"2022","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1541-7786.MCR-18-1235","article-title":"TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease","volume":"17","author":"Baba","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/path.5875","article-title":"GPNMB Expression Identifies TSC1\/2\/mTOR-Associated and MiT Family Translocation-Driven Renal Neoplasms","volume":"257","author":"Salles","year":"2022","journal-title":"J. Pathol."},{"key":"ref_35","first-page":"358","article-title":"[Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis]","volume":"52","author":"Wang","year":"2023","journal-title":"Zhonghua Bing. Li Xue Za Zhi"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/PAS.0000000000002117","article-title":"Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1\/2\/MTOR Alterations From Others","volume":"47","author":"Li","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/PAS.0000000000002435","article-title":"GPNMB Expression Identifies FLCN -Associated Eosinophilic Renal Tumors With Heterogeneous Clinicopathologic Spectrum and Gene Expression Profiles","volume":"49","author":"Xia","year":"2025","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"106122","DOI":"10.1016\/j.humpath.2026.106122","article-title":"Renal Tumors Harboring FLCN Mutations: Case Series from Clinical Practice","volume":"173","author":"Ding","year":"2026","journal-title":"Hum. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"105797","DOI":"10.1016\/j.humpath.2025.105797","article-title":"Evaluation of 3,606 Renal Cell Tumors for TFE3 Rearrangements and TFEB Alterations via Fluorescence in Situ Hybridization, next Generation Sequencing, and GPNMB Immunohistochemistry","volume":"159","author":"Whaley","year":"2025","journal-title":"Hum. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105799","DOI":"10.1016\/j.humpath.2025.105799","article-title":"Unlocking Diagnostic Potential: A Retrospective Analysis of GPNMB Immunohistochemistry in Nearly 1000 Surgical Pathology Specimens","volume":"159","author":"Li","year":"2025","journal-title":"Hum. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate Hydratase-Deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41379-018-0017-7","article-title":"Pattern Multiplicity and Fumarate Hydratase (FH)\/S-(2-Succino)-Cysteine (2SC) Staining but Not Eosinophilic Nucleoli with Perinucleolar Halos Differentiate Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinomas from Kidney Tumors without FH Gene Alteration","volume":"31","author":"Muller","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.humpath.2022.12.013","article-title":"Characterization of Protein S-(2-Succino)-Cysteine (2SC) Succination as a Biomarker for Fumarate Hydratase-Deficient Renal Cell Carcinoma","volume":"134","author":"Mannan","year":"2023","journal-title":"Hum. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cancer: Recognition of the Syndrome by Pathologic Features and the Utility of Detecting Aberrant Succination by Immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1038\/s41467-025-59513-8","article-title":"Comprehensive Molecular Profiling of FH-Deficient Renal Cell Carcinoma Identifies Molecular Subtypes and Potential Therapeutic Targets","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100303","DOI":"10.1016\/j.modpat.2023.100303","article-title":"AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma","volume":"36","author":"Zheng","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.5858\/arpa.2018-0216-RA","article-title":"Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma","volume":"142","author":"Skala","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ccr.2011.08.024","article-title":"An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma","volume":"20","author":"Ooi","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Endo, S., Matsunaga, T., and Nishinaka, T. (2021). The Role of AKR1B10 in Physiology and Pathophysiology. Metabolites, 11.","DOI":"10.3390\/metabo11060332"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/PAS.0000000000001826","article-title":"Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-Deficient Uterine Leiomyomas","volume":"46","author":"Ahvenainen","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_52","first-page":"E250","article-title":"Diagnostic Utility of AKR1B10 Immunostain and Its Expression Across Several Renal Tumor Entities","volume":"148","author":"Kirkham","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"111804","DOI":"10.1016\/j.cellsig.2025.111804","article-title":"DDX24 Inhibits Clear Cell Renal Cell Carcinoma Progression by Directly Regulating AKR1B10","volume":"132","author":"Li","year":"2025","journal-title":"Cell. Signal."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant Succination of Proteins in Fumarate Hydratase-Deficient Mice and HLRCC Patients Is a Robust Biomarker of Mutation Status","volume":"225","author":"Bardella","year":"2011","journal-title":"J. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/hupa.2001.24320","article-title":"Low-Grade Myxoid Renal Epithelial Neoplasms with Distal Nephron Differentiation","volume":"32","author":"Parwani","year":"2001","journal-title":"Hum. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.pas.0000180443.94645.50","article-title":"Immunohistochemical Analysis of Mucinous Tubular and Spindle Cell Carcinoma and Papillary Renal Cell Carcinoma of the Kidney: Significant Immunophenotypic Overlap Warrants Diagnostic Caution","volume":"30","author":"Paner","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/01.pas.0000213271.15221.e3","article-title":"Expanding the Histologic Spectrum of Mucinous Tubular and Spindle Cell Carcinoma of the Kidney","volume":"30","author":"Fine","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/PAS.0000000000001038","article-title":"Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features","volume":"42","author":"Ren","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jcp-2023-208839","article-title":"Gene of the Month: VSTM2A","volume":"77","author":"Wang","year":"2024","journal-title":"J. Clin. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1097\/PAS.0000000000001150","article-title":"VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney","volume":"42","author":"Wang","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/PAS.0000000000001629","article-title":"Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma","volume":"45","author":"Kwon","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"105053","DOI":"10.1016\/j.labinv.2025.105053","article-title":"765 Diagnostic Utility of VSTM2A RNA-ISH in Mucinous Tubular and Spindle Cell Carcinomas: Results from a 331-Tumor Validation Cohort","volume":"106","author":"Abdelwahed","year":"2026","journal-title":"Lab. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/PAP.0000000000000332","article-title":"Chameleon TFE3-Translocation RCC and How Gene Partners Can Change Morphology: Accurate Diagnosis Using Contemporary Modalities","volume":"29","author":"Tretiakova","year":"2022","journal-title":"Adv. Anat. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/his.15560","article-title":"MiT Family Translocation Carcinomas of the Kidney and Related Entities","volume":"88","author":"Argani","year":"2026","journal-title":"Histopathology"},{"key":"ref_65","first-page":"297","article-title":"Comprehensive Analysis of 34 MiT Family Translocation Renal Cell Carcinomas and Review of the Literature: Investigating Prognostic Markers and Therapy Targets","volume":"52","author":"Brunelli","year":"2020","journal-title":"Pathology"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tretiakova, M.S. (2026). Pathobiology and Interactions of the MiTF Signaling Pathways. Adv. Anat. Pathol., Publish Ahead of Print.","DOI":"10.1097\/PAP.0000000000000539"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/gcc.22798","article-title":"Gene Fusion Analysis in Renal Cell Carcinoma by FusionPlex RNA-Sequencing and Correlations of Molecular Findings with Clinicopathological Features","volume":"59","author":"Tretiakova","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/PAS.0000000000001541","article-title":"Morphologic and Immunohistochemical Characteristics of Fluorescent In Situ Hybridization Confirmed TFE3-Gene Fusion Associated Renal Cell Carcinoma: A Single Institutional Cohort","volume":"44","author":"Akgul","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/jclinpath-2020-207372","article-title":"Diagnostic Approach in TFE3-Rearranged Renal Cell Carcinoma: A Multi-Institutional International Survey","volume":"74","author":"Akgul","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41379-021-00803-z","article-title":"TRIM63 Is a Sensitive and Specific Biomarker for MiT Family Aberration-Associated Renal Cell Carcinoma","volume":"34","author":"Wang","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"105862","DOI":"10.1016\/j.humpath.2025.105862","article-title":"Diagnostic Accuracy of TRIM63 RNA-ISH in MiTF-Rearranged Renal Cell Carcinomas: Results from a 331-Tumor Validation Cohort","volume":"161","author":"Lee","year":"2025","journal-title":"Hum. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"103049","DOI":"10.1016\/j.labinv.2024.103049","article-title":"816 TRIM63 RNA in Situ Hybridization (RNA-ISH) Assay: Biomarker Characterization in a Tertiary Clinical Practice","volume":"105","author":"Humble","year":"2025","journal-title":"Lab. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"106035","DOI":"10.1016\/j.humpath.2026.106035","article-title":"RNA in Situ Hybridization Based TRIM63 Characterization in Tubulocystic Renal Cell Carcinoma","volume":"176","author":"Sangoi","year":"2026","journal-title":"Hum. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 Inactivation in Tumor Biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/his.14731","article-title":"Merlin Immunohistochemistry Is Useful in Diagnosis of Tumours within the Spectrum of Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma","volume":"81","author":"Collins","year":"2022","journal-title":"Histopathology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/PAS.0000000000001846","article-title":"NF2-Mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases","volume":"46","author":"Paintal","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/his.15512","article-title":"Merlin-Deficient Renal Cell Carcinoma Often Exhibits High-Grade Cytology, Admixed Architectural Patterns, Sclerotic and Mucinous Stroma, Inflammatory Infiltrates and Calcifications","volume":"87","author":"Liu","year":"2025","journal-title":"Histopathology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-25-2871","article-title":"Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2","volume":"32","author":"Bian","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 Cancer Syndrome: Malignant Mesothelioma, Uveal and Cutaneous Melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cge.12630","article-title":"Comprehensive Review of BAP1 Tumor Predisposition Syndrome with Report of Two New Cases","volume":"89","author":"Rai","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 Loss Defines a New Class of Renal Cell Carcinoma","volume":"44","author":"Liao","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.eururo.2012.09.005","article-title":"Clinical and Pathologic Impact of Select Chromatin-Modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma","volume":"63","author":"Hakimi","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.28521","article-title":"Loss of BAP1 Protein Expression Is an Independent Marker of Poor Prognosis in Patients with Low-Risk Clear Cell Renal Cell Carcinoma","volume":"120","author":"Joseph","year":"2014","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/2767-9764.CRC-25-0069","article-title":"Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies","volume":"5","author":"Lee","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.urology.2007.01.069","article-title":"Immunohistochemical Analysis with Multiple Antibodies in Search of Prognostic Markers for Clear Cell Renal Cell Carcinoma","volume":"69","author":"Phuoc","year":"2007","journal-title":"Urology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3892\/ol.2012.727","article-title":"HER2 Expression in Renal Cell Carcinoma Is Rare and Negatively Correlated with That in Normal Renal Tissue","volume":"4","author":"Wang","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.21873\/cdp.10565","article-title":"HER2 Expression and Nuclear Localization in Clear Cell Renal Cell Carcinoma: Implications for Prognosis and Therapeutic Targeting","volume":"6","author":"Rott","year":"2026","journal-title":"Cancer Diagn. Progn."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1464-410X.2002.02526.x","article-title":"Gene Amplification and Overexpression of HER2 in Renal Cell Carcinoma","volume":"89","author":"Latif","year":"2002","journal-title":"BJU Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"105097","DOI":"10.1016\/j.labinv.2025.105097","article-title":"809 Aberrant Expression of HER2 Is a Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma","volume":"106","author":"Hu","year":"2026","journal-title":"Lab. Investig."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Sapino, A., Goia, M., Recupero, D., and Marchi\u00f2, C. (2013). Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. Front. Oncol., 3.","DOI":"10.3389\/fonc.2013.00129"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Costantini, M., Amoreo, C.A., Torregrossa, L., Al\u00ec, G., Munari, E., Jeronimo, C., Henrique, R., Petronilho, S., Capitanio, U., and Lucian\u00f2, R. (2020). Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication. Cancers, 12.","DOI":"10.3390\/cancers12113345"},{"key":"ref_93","unstructured":"Organisation Mondiale de la Sant\u00e9, and Centre International de Recherche sur le Cancer (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs, World Health Organization Classification of Tumours, International Agency for Research on Cancer."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1097\/PAS.0000000000000962","article-title":"Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis","volume":"41","author":"Saleeb","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.euf.2016.09.002","article-title":"Integrated Phenotypic\/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-Related Pathways, and Implications for Therapy","volume":"4","author":"Saleeb","year":"2018","journal-title":"Eur. Urol. Focus."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/path.70001","article-title":"Papillary Renal Cell Carcinoma with High-ABCC2 Shows an Immune-Evasive Profile Associated with Favorable Response to Immunotherapy","volume":"268","author":"Castillo","year":"2026","journal-title":"J. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/1878-0261.12346","article-title":"Modulating ATP Binding Cassette Transporters in Papillary Renal Cell Carcinoma Type 2 Enhances Its Response to Targeted Molecular Therapy","volume":"12","author":"Saleeb","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.humpath.2021.12.006","article-title":"ABCC2 Expression in Papillary Renal Cell Carcinoma Provides Better Prognostic Stratification than WHO\/ISUP Nucleolar Grade","volume":"120","author":"Saleeb","year":"2022","journal-title":"Hum. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cam4.2769","article-title":"Concordance of PD-1 and PD-L1 (B7-H1) in Paired Primary and Metastatic Clear Cell Renal Cell Carcinoma","volume":"9","author":"Ho","year":"2020","journal-title":"Cancer Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma: Extended Follow-up of Efficacy and Safety Results from a Randomised, Controlled, Phase 3 Trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Clear Cell Renal Cell Carcinoma: 5-Year Survival and Biomarker Analyses of the Phase 3 KEYNOTE-426 Trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"102034","DOI":"10.1016\/j.esmoop.2023.102034","article-title":"Efficacy of Avelumab plus Axitinib versus Sunitinib by Numbers of IMDC Risk Factors and Target Tumor Sites at Baseline in Advanced Renal Cell Carcinoma: Long-Term Follow-up Results from JAVELIN Renal 101","volume":"8","author":"Tomita","year":"2023","journal-title":"ESMO Open"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","article-title":"Programmed Death Ligand-1 (PD-L1) as a Predictive Marker for Immunotherapy in Solid Tumours: A Guide to Immunohistochemistry Implementation and Interpretation","volume":"53","author":"Paver","year":"2021","journal-title":"Pathology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2174\/1389450121666200324151056","article-title":"PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay","volume":"21","author":"Cimadamore","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Simonaggio, A., Epaillard, N., Pobel, C., Moreira, M., Oudard, S., and Vano, Y.-A. (2021). Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). Cancers, 13.","DOI":"10.3390\/cancers13020231"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Shiuan, E., Reddy, A., Dudzinski, S.O., Lim, A.R., Sugiura, A., Hongo, R., Young, K., Liu, X.-D., Smith, C.C., and O\u2019Neal, J. (2021). Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1\/PD-L1 in Renal Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13061475"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e024691","DOI":"10.1136\/bmjopen-2018-024691","article-title":"Targeted Therapies for Previously Treated Advanced or Metastatic Renal Cell Carcinoma: Systematic Review and Network Meta-Analysis","volume":"9","author":"Karner","year":"2019","journal-title":"BMJ Open"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and Predictive Biomarkers for Immunotherapy in Advanced Renal Cell Carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat. Rev. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3072\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:24:08Z","timestamp":1790069048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":109,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193072"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193072","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}